1. Home
  2. CTKB vs MLYS Comparison

CTKB vs MLYS Comparison

Compare CTKB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.71

Market Cap

433.8M

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.26

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
MLYS
Founded
1990
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.8M
3.1B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
CTKB
MLYS
Price
$4.71
$36.26
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$5.88
$46.40
AVG Volume (30 Days)
1.9M
1.7M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,828,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$8.24
52 Week High
$7.30
$47.65

Technical Indicators

Market Signals
Indicator
CTKB
MLYS
Relative Strength Index (RSI) 43.99 39.06
Support Level $4.79 $35.73
Resistance Level $5.16 $39.15
Average True Range (ATR) 0.24 1.94
MACD -0.12 -0.50
Stochastic Oscillator 14.68 8.08

Price Performance

Historical Comparison
CTKB
MLYS

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: